<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2098">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04309253</url>
  </required_header>
  <id_info>
    <org_study_id>201800984A0</org_study_id>
    <nct_id>NCT04309253</nct_id>
  </id_info>
  <brief_title>The Influence of Vascular Burden, Amyloid Plaque and Tau Protein in Patients With Vascular Cognitive Impairment and Dementia With Tauopathy</brief_title>
  <official_title>The Influence of Vascular Burden, Amyloid Plaque and Tau Protein in Patients With Vascular Cognitive Impairment and Dementia With Tauopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and objects： Amyloid plaques and tau protein are the landmarks of&#xD;
      neurodegeneration in Alzheimer's disease (AD). On the other hand, it is reported that&#xD;
      cerebral ischemia may induce amyloid plaques and tau protein accumulation. However, it was&#xD;
      difficult to in vivo disentangle the complex and dynamic interactions between AD&#xD;
      pathophysiology and cerebral vascular injury during the post-stroke cognitive impairment&#xD;
      development in the past. With the advent of novel radiotracers specific to cerebral amyloid&#xD;
      plaques and tau protein, we aim to conduct a prospective multimodal neuroimaging cohort study&#xD;
      to investigate the contribution of vascular injury, amyloid plaque and tau protein to&#xD;
      cognitive impairment.&#xD;
&#xD;
      Subjects and methods： The prospective project plans to recruit patients with vascular&#xD;
      cognitive impairment (VCI) (Group A, n=200), Alzheimer's disease/mild cognitive impairment&#xD;
      (MCI) (Group B, n = 200), and fronto-temporal dementia (FTD) (Group C, n =30). In addition,&#xD;
      another 60 healthy people will be recruited as the control group (Group D, n=60). [18F]AV45&#xD;
      and [18F]MNI-958(PMPBB3) PET will be done for imaging cerebral amyloid plaque and tau protein&#xD;
      distribution, brain MRI for obtaining structural and functional information, and&#xD;
      neuropsychological tests for cognitive performance. Cognitive evaluation will be repeated 18&#xD;
      months after recruitment. In addition, APOE genotyping and carotid ultrasound will be&#xD;
      performed as well.&#xD;
&#xD;
      By obtaining the neuroimaging information, such as severity of white matter change and&#xD;
      infarction, cortical and hippocampal atrophy, and SUVRs of [18F]AV-45 and&#xD;
      [18F]MNI-958(PMPBB3) PET, the study will be able to investigate the composite influence of&#xD;
      cerebrovascular disease and neurodegenerative pathology on the trajectory of cognitive&#xD;
      impairment. Group comparisons will be performed using the Chi-square test, independent t&#xD;
      test, Mann-Whitney U test, ANOVA test, and multiple linear regression, where appropriate.&#xD;
&#xD;
      Anticipation： In this project, we will able to explore the distribution patterns of amyloid&#xD;
      plaque and tau protein among dementia patients with different etiologies, and also evaluate&#xD;
      their influence on cognition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2018</start_date>
  <completion_date type="Anticipated">September 18, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 18, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A. Group A: Patients with vascular cognitive impairment (VCI), n=80. B. Group B: Alzheimer's disease/mild cognitive impairment (MCI), n=80. C. Group C: Fronto-temporal dementia (FTD), n=30. D. Group D: Normal control, n=30.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Clinical Dementia Rating-Sum of Boxes (CDR-SB) change score</measure>
    <time_frame>through study completion, an average of 1.5 year</time_frame>
    <description>The Clinical Dementia Rating-Sum of Boxes (CDR-SB) change score between baseline and 18-month follow-up will be calculated for primary endpoint determination. Two-sample independent t-test will be performed to compare the CDR-SB change score between patients positive and negative for tau protein accumulation. Patients will be stratified into tau-positive and tau-negative groups, and the presentations of their cognitive state will be recorded at the 18-month follow-up visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chi-square test will be performed to analyze dementia conversion rate.</measure>
    <time_frame>through study completion, an average of 1.5 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia</condition>
  <arm_group>
    <arm_group_label>PMPBB3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Primary endpoint(s):&#xD;
A. To determine the distribution patterns of cerebral amyloid plaques and Tau protein among AD/MCI, VCI and FTP patients as well as normal controls.&#xD;
Secondary endpoints:&#xD;
A. To correlate vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention with clinical presentation and cognitive performance among different groups of subjects B. To determine the impacts of vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention changes on cognitive trajectory over the 18-month follow-up period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AV45</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Primary endpoint(s):&#xD;
A. To determine the distribution patterns of cerebral amyloid plaques and Tau protein among AD/MCI, VCI and FTP patients as well as normal controls.&#xD;
Secondary endpoints:&#xD;
A. To correlate vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention with clinical presentation and cognitive performance among different groups of subjects B. To determine the impacts of vascular burden, [18F]AV45 and [18F]MNI-958(PMPBB3) retention changes on cognitive trajectory over the 18-month follow-up period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PMPBB3</intervention_name>
    <description>F-18 PMPBB3 PET Imaging</description>
    <arm_group_label>AV45</arm_group_label>
    <arm_group_label>PMPBB3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AV45</intervention_name>
    <description>F-18 AV45 PET Imaging</description>
    <arm_group_label>AV45</arm_group_label>
    <arm_group_label>PMPBB3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Inclusion criteria for VCI (Group A, n=80)&#xD;
&#xD;
               -  Males or females with age &gt;= 20 years old.&#xD;
&#xD;
               -  Patients fulfill the AHA/ASA criteria for vascular cognitive impairment.&#xD;
&#xD;
               -  Provision of signed informed consent from the subject and the subject's legally&#xD;
                  authorized representative or caregiver (if applicable).&#xD;
&#xD;
               -  The subject has an appropriate caregiver capable of accompanying the subject, if&#xD;
                  necessary.&#xD;
&#xD;
          2. Inclusion criteria for AD / MCI (Group B, n=80)&#xD;
&#xD;
               -  Males or females with age &gt;= 20 years old.&#xD;
&#xD;
               -  Patients fulfill the National Institute on Aging (NIA) - Alzheimer's Association&#xD;
                  Diagnostic Guidelines.&#xD;
&#xD;
               -  Provision of signed informed consent from the subject and the subject's legally&#xD;
                  authorized representative or caregiver (if applicable).&#xD;
&#xD;
               -  The subject has an appropriate caregiver capable of accompanying the subject, if&#xD;
                  necessary.&#xD;
&#xD;
          3. Inclusion criteria for FTD (Group C, n=30)&#xD;
&#xD;
               -  Males or females with age &gt;= 20 years old.&#xD;
&#xD;
               -  Patients fulfill the criteria of probable FTD.&#xD;
&#xD;
               -  Provision of signed informed consent from the subject and the subject's legally&#xD;
                  authorized representative or caregiver (if applicable).&#xD;
&#xD;
               -  The subject has an appropriate caregiver capable of accompanying the subject, if&#xD;
                  necessary.&#xD;
&#xD;
          4. Inclusion criteria for normal control (Group D, n=30)&#xD;
&#xD;
               -  Males or females with age &gt;= 20 years old.&#xD;
&#xD;
               -  Provision of signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy less than 1 year.&#xD;
&#xD;
          -  Clinically significant abnormal laboratory values (such as AST/ALT &gt;= 3X of upper&#xD;
             normal limits).&#xD;
&#xD;
          -  Clinically significant or unstable medical or psychiatric illness.&#xD;
&#xD;
          -  Epilepsy history.&#xD;
&#xD;
          -  Cognitive impairment resulting from trauma or brain damage.&#xD;
&#xD;
          -  Substance abuse or alcoholism in the past 3 months.&#xD;
&#xD;
          -  Stroke history within the recent 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huang Kuo-Lun, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Stroke Section, Department of Neurology, Chang-Gung memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huang Kuo-Lun, M.D.</last_name>
    <phone>+886-3-3281200</phone>
    <phone_ext>8340</phone_ext>
    <email>drkuolun@cgmh.org.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chen Jing-Fang</last_name>
    <phone>+886-3-3281200</phone>
    <phone_ext>8413</phone_ext>
    <email>tp6tp6fg@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology, Chang-Gung memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <state>Guishan</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huang Kuo-Lun, M.D.</last_name>
      <phone>+886-3-3281200</phone>
      <phone_ext>8340</phone_ext>
      <email>drkuolun@cgmh.org.tw</email>
    </contact>
    <contact_backup>
      <last_name>Chen Jing-Fang</last_name>
      <phone>+886-3-3281200</phone>
      <phone_ext>8413</phone_ext>
      <email>tp6tp6fg@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 10, 2020</study_first_submitted>
  <study_first_submitted_qc>March 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <last_update_submitted>October 3, 2021</last_update_submitted>
  <last_update_submitted_qc>October 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vascular cognitive impairment, Alzheimer's disease, fronto-temporal dementia, amyloid plaque, tau protein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Tauopathies</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Plaque, Amyloid</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

